These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 16595032)

  • 1. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer.
    Ocaña A; Hortobagyi GN; Esteva FJ
    Clin Breast Cancer; 2006 Feb; 6(6):495-504. PubMed ID: 16595032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line chemotherapy for metastatic breast cancer.
    Telli ML; Carlson RW
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S66-72. PubMed ID: 19596645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
    Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
    Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
    Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in chemotherapy for HER2-negative metastatic breast cancer.
    Mukai H; Ito M
    Chin Clin Oncol; 2018 Jun; 7(3):26. PubMed ID: 30056728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic Strategies for advanced breast cancer.
    Briest S; Stearns V
    Oncology (Williston Park); 2007 Oct; 21(11):1325-35; discussion 1338, 1340. PubMed ID: 18080617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of chemotherapy for metastatic breast cancer.
    Miller KD; Sledge GW
    Hematol Oncol Clin North Am; 1999 Apr; 13(2):415-34. PubMed ID: 10363138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer.
    Cianfrocca M; Gradishar WJ
    J Natl Compr Canc Netw; 2007 Sep; 5(8):673-5. PubMed ID: 17927925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point: combination versus single-agent chemotherapy: the argument for sequential single agents.
    Conlin AK; Seidman AD
    J Natl Compr Canc Netw; 2007 Sep; 5(8):668-72. PubMed ID: 17927924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group.
    Chlebowski RT; Smalley RV; Weiner JM; Irwin LE; Bartolucci AA; Bateman JR
    Br J Cancer; 1989 Feb; 59(2):227-30. PubMed ID: 2649130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?
    Seidman AD
    J Clin Oncol; 2003 Feb; 21(4):577-9. PubMed ID: 12586789
    [No Abstract]   [Full Text] [Related]  

  • 19. How to improve cytotoxic therapy in advanced breast cancer.
    Bastholt L; Mouridsen HT
    Acta Oncol; 1990; 29(3):349-55. PubMed ID: 2194536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for cytostatic therapy in metastatic breast cancer.
    Kvinnsland S
    Acta Oncol; 1992; 31(2):215-8. PubMed ID: 1622636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.